Mechanism of Inhibition of Cholesteryl Ester Transfer Protein by Small Molecule Inhibitors

Journal of Physical Chemistry B

Volumn 120, Issue 33, 2016, Pages 8254-8263

  Chirasani, Venkat R ^a   Sankar, Revathi ^a   Senapati, Sanjib ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY MADRAS   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; ENZYME INHIBITION; ESTERS; HYDROPHOBICITY; LIPIDS; LIPOPROTEINS; MOLECULAR DYNAMICS; MOLECULES; PROTEINS;

CARDIO-VASCULAR DISEASE; CHOLESTERYL ESTER TRANSFER PROTEINS; DRUG DISCOVERY PROCESS; HIGH DENSITY LIPOPROTEIN; HYDROPHOBIC INTERACTIONS; MOLECULAR DYNAMICS SIMULATIONS; SMALL MOLECULE INHIBITOR; VERY LOW DENSITY LIPOPROTEINS;

PRINCIPAL COMPONENT ANALYSIS;

ANACETRAPIB; BENZAMIDE DERIVATIVE; BENZYLAMINE DERIVATIVE; BMS-795311; CETP PROTEIN, HUMAN; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; HYPOCHOLESTEROLEMIC AGENT; OXAZOLIDINONE DERIVATIVE; PROTEIN BINDING; TRIACYLGLYCEROL;

ALPHA HELIX; ANTAGONISTS AND INHIBITORS; BETA SHEET; BINDING SITE; CHEMICAL PHENOMENA; CHEMISTRY; ENZYME SPECIFICITY; HUMAN; KINETICS; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR LIBRARY; PRINCIPAL COMPONENT ANALYSIS; PROTEIN DOMAIN; THERMODYNAMICS; X RAY CRYSTALLOGRAPHY;

ANTICHOLESTEREMIC AGENTS; BENZAMIDES; BENZYLAMINES; BINDING SITES; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL ESTERS; CRYSTALLOGRAPHY, X-RAY; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; KINETICS; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; OXAZOLIDINONES; PRINCIPAL COMPONENT ANALYSIS; PROTEIN BINDING; PROTEIN CONFORMATION, ALPHA-HELICAL; PROTEIN CONFORMATION, BETA-STRAND; PROTEIN INTERACTION DOMAINS AND MOTIFS; SMALL MOLECULE LIBRARIES; SUBSTRATE SPECIFICITY; THERMODYNAMICS; TRIGLYCERIDES;

EID: 84984876329     PISSN: 15206106     EISSN: 15205207     Source Type: Journal    
DOI: 10.1021/acs.jpcb.6b01928     Document Type: Article

References (48)

1. Barter, P. J. Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis Arterioscler., Thromb., Vasc. Biol. 2003, 23, 160-167 10.1161/01.ATV.0000054658.91146.64
2. Zhong, S.; Sharp, D. S.; Grove, J. S.; Bruce, C.; Yano, K.; Curb, J. D.; Tall, A. R. Increased Coronary Heart Disease in Japanese-American Men with Mutation in the Cholesteryl Ester Transfer Protein Gene despite Increased HDL Levels J. Clin. Invest. 1996, 97, 2917-2923 10.1172/JCI118751
3. Okamoto, H.; Yonemori, F.; Wakitani, K.; Minowa, T.; Maeda, K.; Shinkai, H. A Cholesteryl Ester Transfer Protein Inhibitor Attenuates Atherosclerosis in Rabbits Nature 2000, 406, 203-207 10.1038/35018119
4. Morehouse, L. a; Sugarman, E. D.; Bourassa, P.-A.; Sand, T. M.; Zimetti, F.; Gao, F.; Rothblat, G. H.; Milici, A. J. Inhibition of CETP Activity by Torcetrapib Reduces Susceptibility to Diet-Induced Atherosclerosis in New Zealand White Rabbits J. Lipid Res. 2007, 48, 1263-1272 10.1194/jlr.M600332-JLR200
5. Gordon, T.; Castelli, W. P.; Hjortland, M. C.; Kannel, W. B.; Dawber, T. R. High Density Lipoprotein as a Protective Factor against Coronary Heart Disease Am. J. Med. 1977, 62, 707-714 10.1016/0002-9343(77)90874-9
6. Inazu, A.; Brown, M. L.; Hesler, C. B.; Agellon, L. B.; Koizumi, J.; Takata, K.; Maruhama, Y.; Mabuchi, H.; Tall, A. R. Increased High-Density Lipoprotein Levels Caused by a Common Cholesteryl-Ester Transfer Protein Gene Mutation N. Engl. J. Med. 1990, 323, 1234-1238 10.1056/NEJM199011013231803
7. Linsel-Nitschke, P.; Tall, A. R. HDL as a Target in the Treatment of Atherosclerotic Cardiovascular Disease Nat. Rev. Drug Discovery 2005, 4, 193-205 10.1038/nrd1658
8. Dullaart, R. P. F.; Dallinga-Thie, G. M.; Wolffenbuttel, B. H. R.; van Tol, A. CETP Inhibition in Cardiovascular Risk Management: A Critical Appraisal Eur. J. Clin. Invest. 2007, 37, 90-98 10.1111/j.1365-2362.2007.01756.x
9. Joy, T.; Hegele, R. A. Is Raising HDL a Futile Strategy for Atheroprotection? Nat. Rev. Drug Discovery 2008, 7, 143-155 10.1038/nrd2489
10. Cannon, C. P. HIgh-Density Lipoprotein Cholesterol as the Holy Grail JAMA 2011, 306, 2153-2155 10.1001/jama.2011.1687
11. The Atlas of Heart Disease and Stroke; World Health Organization: Geneva, Switzerland, 2008.
12. Ruggeri, R. B. Cholesteryl Ester Transfer Protein: Pharmacological Inhibition for the Modulation of Plasma Cholesterol Levels and Promising Target for the Prevention of Atherosclerosis Curr. Top. Med. Chem. 2005, 5, 257-264 10.2174/1568026053544506
13. Krishna, R.; Anderson, M. S.; Bergman, A. J.; Jin, B.; Fallon, M.; Cote, J.; Rosko, K.; Chavez-Eng, C.; Lutz, R.; Bloomfield, D. M. et al. Effect of the Cholesteryl Ester Transfer Protein Inhibitor, Anacetrapib, on Lipoproteins in Patients with Dyslipidaemia and on 24-H Ambulatory Blood Pressure in Healthy Individuals: Two Double-Blind, Randomised Placebo-Controlled Phase I Studies Lancet 2007, 370, 1907-1914 10.1016/S0140-6736(07)61813-3
14. Cao, G.; Beyer, T. P.; Zhang, Y.; Schmidt, R. J.; Chen, Y. Q.; Cockerham, S. L.; Zimmerman, K. M.; Karathanasis, S. K.; Cannady, E. A.; Fields, T. et al. Evacetrapib Is a Novel, Potent, and Selective Inhibitor of Cholesteryl Ester Transfer Protein That Elevates HDL Cholesterol without Inducing Aldosterone or Increasing Blood Pressure J. Lipid Res. 2011, 52, 2169-2176 10.1194/jlr.M018069
15. Barter, P. J.; Caulfield, M.; Eriksson, M.; Grundy, S. M.; Kastelein, J. J. P.; Komajda, M.; Lopez-Sendon, J.; Mosca, L.; Tardif, J.-C.; Waters, D. D. et al. Effects of Torcetrapib in Patients at High Risk for Coronary Events N. Engl. J. Med. 2007, 357, 2109-2122 10.1056/NEJMoa0706628
16. Bots, M. L.; Visseren, F. L.; Evans, G. W.; Riley, W. A.; Revkin, J. H.; Tegeler, C. H.; Shear, C. L.; Duggan, W. T.; Vicari, R. M.; Grobbee, D. E. et al. Torcetrapib and Carotid Intima-Media Thickness in Mixed Dyslipidaemia (RADIANCE 2 Study): A Randomised, Double-Blind Trial Lancet 2016, 370, 153-160 10.1016/S0140-6736(07)61088-5
17. Schwartz, G. G.; Olsson, A. G.; Abt, M.; Ballantyne, C. M.; Barter, P. J.; Brumm, J.; Chaitman, B. R.; Holme, I. M.; Kallend, D.; Leiter, L. A. et al. Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome N. Engl. J. Med. 2012, 367, 2089-2099 10.1056/NEJMoa1206797
18. Mullard, A. CETP Set-Back, Again Nat. Rev. Drug Discovery 2015, 14, 739-739 10.1038/nrd4781
19. Qiao, J. X.; Wang, T. C.; Adam, L. P.; Chen, A. Y. A.; Taylor, D. S.; Yang, R. Z.; Zhuang, S.; Sleph, P. G.; Li, J. P.; Li, D. et al. Triphenylethanamine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors: Discovery of N-[(1R)-1-(3-Cyclopropoxy-4-Fluorophenyl)-1-[3-Fluoro-5-(1,1,2,2-Tetrafluoroethoxy)phenyl]-2-Phenylethyl]-4-Fluoro-3-(Trifluoromethyl)benzamide (BMS-795311) J. Med. Chem. 2015, 58, 9010-9026 10.1021/acs.jmedchem.5b01363
20. Qiu, X.; Mistry, A.; Ammirati, M. J.; Chrunyk, B. a; Clark, R. W.; Cong, Y.; Culp, J. S.; Danley, D. E.; Freeman, T. B.; Geoghegan, K. F. et al. Crystal Structure of Cholesteryl Ester Transfer Protein Reveals a Long Tunnel and Four Bound Lipid Molecules Nat. Struct. Mol. Biol. 2007, 14, 106-113 10.1038/nsmb1197
21. Hamilton, J. A. Fatty Acid Interactions with Proteins: What X-Ray Crystal and NMR Solution Structures Tell Us Prog. Lipid Res. 2004, 43, 177-199 10.1016/j.plipres.2003.09.002
22. Bruce, C.; Beamer, L. J.; Tall, A. R. The Implications of the Structure of the Bactericidal/permeability-Increasing Protein on the Lipid-Transfer Function of the Cholesteryl Ester Transfer Protein Curr. Opin. Struct. Biol. 1998, 8, 426-434 10.1016/S0959-440X(98)80118-8
23. Kawano, K.; Qin, S. C.; Lin, M.; Tall, A. R.; Jiang, X. C. Cholesteryl Ester Transfer Protein and Phospholipid Transfer Protein Have Nonoverlapping Functions in Vivo J. Biol. Chem. 2000, 275, 29477-29481 10.1074/jbc.M003523200
24. Wang, S.; Deng, L.; Milne, R. W.; Tall, A. R. Identification of a Sequence within the C-Terminal 26 Amino Acids of Cholesteryl Ester Transfer Protein Responsible for Binding a Neutralizing Monoclonal Antibody and Necessary for Neutral Lipid Transfer Activity J. Biol. Chem. 1992, 267, 17487-17490
25. Äijänen, T.; Koivuniemi, A.; Javanainen, M.; Rissanen, S.; Rog, T.; Vattulainen, I. How Anacetrapib Inhibits the Activity of the Cholesteryl Ester Transfer Protein? Perspective through Atomistic Simulations PLoS Comput. Biol. 2014, 10, e1003987 10.1371/journal.pcbi.1003987
26. Mantlo, N. B.; Escribano, A. Update on the Discovery and Development of Cholesteryl Ester Transfer Protein Inhibitors for Reducing Residual Cardiovascular Risk J. Med. Chem. 2014, 57, 1-17 10.1021/jm400574e
27. Sikorski, J. A. Oral Cholesteryl Ester Transfer Protein (CETP) Inhibitors: A Potential New Approach for Treating Coronary Artery Disease J. Med. Chem. 2006, 49, 1-22 10.1021/jm058224l
28. Liu, S.; Mistry, A.; Reynolds, J. M.; Lloyd, D. B.; Griffor, M. C.; Perry, D. a; Ruggeri, R. B.; Clark, R. W.; Qiu, X. Crystal Structures of Cholesteryl Ester Transfer Protein in Complex with Inhibitors J. Biol. Chem. 2012, 287, 37321-37329 10.1074/jbc.M112.380063
29. Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. J. AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility J. Comput. Chem. 2009, 30, 2785-2791 10.1002/jcc.21256
30. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. A.; et al., Gaussian 09; Gaussian, Inc.: Wallingford, CT, 2009.
31. Webb, B.; Sali, A. Comparative Protein Structure Modeling Using Modeller Curr. Protoc. Bioinformatics. 2014, 47, 5.6.1-5.6.32 10.1002/0471250953.bi0506s47
32. Schuler, L. D.; Daura, X.; van Gunsteren, W. F. An Improved GROMOS96 Force Field for Aliphatic Hydrocarbons in the Condensed Phase J. Comput. Chem. 2001, 22, 1205-1218 10.1002/jcc.1078
33. Berger, O.; Edholm, O.; Jähnig, F. Molecular Dynamics Simulations of a Fluid Bilayer of Dipalmitoylphosphatidylcholine at Full Hydration, Constant Pressure, and Constant Temperature Biophys. J. 1997, 72, 2002-2013 10.1016/S0006-3495(97)78845-3
34. Koivuniemi, A.; Heikelä, M.; Kovanen, P. T.; Vattulainen, I.; Hyvönen, M. T. Atomistic Simulations of Phosphatidylcholines and Cholesteryl Esters in High-Density Lipoprotein-Sized Lipid Droplet and Trilayer: Clues to Cholesteryl Ester Transport and Storage Biophys. J. 2009, 96, 4099-4108 10.1016/j.bpj.2009.01.058
35. Siu, S. W. I.; Vácha, R.; Jungwirth, P.; Böckmann, R. A. Biomolecular Simulations of Membranes: Physical Properties from Different Force Fields J. Chem. Phys. 2008, 128, 125103 10.1063/1.2897760
36. Malde, A. K.; Zuo, L.; Breeze, M.; Stroet, M.; Poger, D.; Nair, P. C.; Oostenbrink, C.; Mark, A. E. An Automated Force Field Topology Builder (ATB) and Repository: Version 1.0 J. Chem. Theory Comput. 2011, 7, 4026-4037 10.1021/ct200196m
37. Vriend, G. WHAT IF: A Molecular Modeling and Drug Design Program J. Mol. Graphics 1990, 8, 52-56 10.1016/0263-7855(90)80070-V
38. Essmann, U.; Perera, L.; Berkowitz, M. L.; Darden, T.; Lee, H.; Pedersen, L. G. A Smooth Particle Mesh Ewald Method J. Chem. Phys. 1995, 103, 8577-8593 10.1063/1.470117
39. Hess, B.; Kutzner, C.; van der Spoel, D.; Lindahl, E. GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation J. Chem. Theory Comput. 2008, 4, 435-447 10.1021/ct700301q
40. Berendsen, H. J.; Hayward, S. Collective Protein Dynamics in Relation to Function Curr. Opin. Struct. Biol. 2000, 10, 165-169 10.1016/S0959-440X(00)00061-0
41. Natarajan, K.; Senapati, S. Probing the Conformational Flexibility of Monomeric FtsZ in GTP-Bound, GDP-Bound, and Nucleotide-Free States Biochemistry 2013, 52, 3543-3551 10.1021/bi400170f
42. Humphrey, W.; Dalke, A.; Schulten, K. VMD: Visual Molecular Dynamics J. Mol. Graphics 1996, 14, 33-38 10.1016/0263-7855(96)00018-5
43. Chovancova, E.; Pavelka, A.; Benes, P.; Strnad, O.; Brezovsky, J.; Kozlikova, B.; Gora, A.; Sustr, V.; Klvana, M.; Medek, P. et al. CAVER 3.0: A Tool for the Analysis of Transport Pathways in Dynamic Protein Structures PLoS Comput. Biol. 2012, 8, e1002708 10.1371/journal.pcbi.1002708
44. Laskowski, R. A.; Swindells, M. B. LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery J. Chem. Inf. Model. 2011, 51, 2778-2786 10.1021/ci200227u
45. 50) of an Enzymatic Reaction Biochem. Pharmacol. 1973, 22, 3099-3108 10.1016/0006-2952(73)90196-2
46. Clark, R. W.; Ruggeri, R. B.; Cunningham, D.; Bamberger, M. J. Description of the Torcetrapib Series of Cholesteryl Ester Transfer Protein Inhibitors, Including Mechanism of Action J. Lipid Res. 2006, 47, 537-552 10.1194/jlr.M500349-JLR200
47. Äijänen, T. Investigation of Interactions between Cholesteryl Ester Transfer Protein and Anacetrapib by using Molecular Simulations. Master of Science Thesis, Tampere University of Technology, Tampere, Finland, 2012; p 51.
48. Zhang, L.; Yan, F.; Zhang, S.; Lei, D.; Charles, M. A.; Cavigiolio, G.; Oda, M.; Krauss, R. M.; Weisgraber, K. H.; Rye, K.-A. et al. Structural Basis of Transfer between Lipoproteins by Cholesteryl Ester Transfer Protein Nat. Chem. Biol. 2012, 8, 342-349 10.1038/nchembio.796